In the BioHarmony Drug Report Database

"Preview" Icon

Methylnaltrexone

Relistor (methylnaltrexone) is a small molecule pharmaceutical. Methylnaltrexone was first approved as Relistor on 2008-04-24. It is used to treat constipation in the USA. It has been approved in Europe to treat constipation and opioid-related disorders. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target kappa-type opioid receptor and delta-type opioid receptor. Relistor’s patents are valid until 2031-03-10 (FDA).

 

Trade Name

 

Relistor
 

Common Name

 

methylnaltrexone
 

ChEMBL ID

 

CHEMBL1186579
 

Indication

 

constipation, opioid-related disorders
 

Drug Class

 

Narcotic agonists/antagonists (normorphine type)

Image (chem structure or protein)

Methylnaltrexone structure rendering